search button
Open Access

Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID‑19 pandemic: A single tertiary center experience

  • Authors:
    • Marwan Al-Hajeili
    • Reem Ujaimi
    • Omar Iskanderani
    • Nora Trabulsi
    • Somayah Bawazeer

  • View Affiliations

  • Published online on: November 1, 2022     https://doi.org/10.3892/ol.2022.13574
  • Article Number: 454

  • Copyright: © Al-Hajeili et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is the most common cancer type in women in Saudi Arabia (SA). Globally, cancer treatment has been affected by the recent COVID‑19 pandemic. The present retrospective study reviews the 30‑day morbidity and mortality rates of patients with breast cancer receiving anticancer systemic treatment before (group1) and during the peak of the COVID‑19 (group 2) pandemic at a tertiary center, King Abdulaziz University Hospital (Jeddah, SA). There were no differences between the two groups regarding sex, age, breast cancer stage distribution, intention to treat or class of anticancer treatment received. Patients treated during the peak pandemic period received delayed treatment. No statistically significant difference was observed in the 30‑day morbidity or mortality rates, although there was a trend towards higher rates of morbidity among patients treated during the peak of the pandemic period. In group 2, only 2.3% of the patients tested positive for COVID‑19, and there was no significant difference in the 30‑day morbidity and mortality rates between COVID‑positive and COVID‑negative patients receiving anticancer treatment. Individuals with breast cancer are a vulnerable group of patients that should be treated with special care during pandemics or other crises that affect the health care system.
View References

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Al-Hajeili M, Ujaimi R, Iskanderani O, Trabulsi N and Bawazeer S: Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID‑19 pandemic: A single tertiary center experience. Oncol Lett 24: 454, 2022
APA
Al-Hajeili, M., Ujaimi, R., Iskanderani, O., Trabulsi, N., & Bawazeer, S. (2022). Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID‑19 pandemic: A single tertiary center experience. Oncology Letters, 24, 454. https://doi.org/10.3892/ol.2022.13574
MLA
Al-Hajeili, M., Ujaimi, R., Iskanderani, O., Trabulsi, N., Bawazeer, S."Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID‑19 pandemic: A single tertiary center experience". Oncology Letters 24.6 (2022): 454.
Chicago
Al-Hajeili, M., Ujaimi, R., Iskanderani, O., Trabulsi, N., Bawazeer, S."Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID‑19 pandemic: A single tertiary center experience". Oncology Letters 24, no. 6 (2022): 454. https://doi.org/10.3892/ol.2022.13574